Reviva will present new analyses on negative symptoms with brilaroxazine from its Phase 3 RECOVER double‑blind trial in acutely exacerbated schizophrenia and from a one‑year open‑label extension in clinically stable patients at CNS Summit 2025 in Boston. The poster, “Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year” (Poster 32), is slated for the evening sessions on November 3–4.
The core event is a targeted data reveal focused on a notoriously difficult domain in schizophrenia. Rather than topline efficacy or safety, Reviva is isolating negative symptom readouts across two distinct clinical contexts—acute decompensation under randomized conditions and long‑term, uncontrolled follow‑up in stabilized patients. For a late‑stage asset, this is a deliberate signal to position brilaroxazine beyond acute symptom control and into functional domains that drive disability, caregiver burden, and payer scrutiny.
Strategically, highlighting negative symptoms at this juncture looks like pre‑label shaping and a differentiation bid ahead of pivotal or registrational moves. If RECOVER’s primary analyses were centered on overall symptom reduction in acute exacerbation, the negative symptom subset could be either a pre‑specified secondary endpoint or an exploratory slice. Pairing it with a one‑year open‑label trajectory in stable patients aims to suggest durability and translational relevance to real‑world maintenance. The tension is evident: regulators have long cautioned that improvements in negative symptoms during acute episodes can be confounded by concurrent relief of positive symptoms or sedation effects. In contrast, open‑label data in stable populations lack control and can overestimate effect size. Presenting both angles allows Reviva to imply breadth while still leaving the question of causality and clinical meaning open.
For sites and CROs, the immediate relevance is operational. Negative symptom measurement demands tight rater calibration, consistent application of scales, and mitigation of placebo and expectancy effects. If Reviva is gearing up for a dedicated negative symptom program—or for labeling discussions that lean on functional outcomes—expect heavier reliance on centralized ratings, inter‑rater reliability monitoring, and possibly hybrid visit schedules to support long‑horizon retention. Sites will want to know which scale was used, how it was anchored, and whether any digital adjuncts were deployed to reduce variability. In the open‑label extension, adherence management, retention strategies, and safety surveillance over the course of a year will be instructive for maintenance‑phase study design and resource planning.
For sponsors and payers, the practical question is whether any signal translates into meaningful functional improvement and healthcare utilization impact. If the analyses map to robust changes on established negative symptom scales with concurrent gains in functioning, that bolsters the case for reimbursement differentiation. Without that, improvements that are statistically significant but modest or confounded will struggle to move payer algorithms. Regulators will look for separation from placebo in acute settings that can’t be explained by positive symptom shifts, and for controlled evidence in stable patients with predominant negative symptoms—criteria that open‑label trajectories cannot satisfy alone.
What to watch next is whether Reviva discloses the magnitude of change, responder thresholds, timing of onset, and maintenance of effect across both analyses, along with safety and metabolic signals over the one‑year horizon. Equally important is clarity on whether these were pre‑specified endpoints and how missing data were handled. The company’s next move will indicate intent: a dedicated, controlled negative symptom trial in stable patients would align with regulatory expectations, while advancing directly toward submission would hinge on broader efficacy and safety data already in hand. Until then, this poster is best read as groundwork for a differentiation narrative that must still be validated under the stricter designs adverse symptom claims typically require.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
